The trial demonstrated highly statistically significant results for all primary and secondary endpoints (p0.0001), reported in October 2024, indicating Ameluz-PDT's safety and efficacy in treating ...

The trial included 81 patients, with a notable 57.5% remission rate for those treated with GH001 compared to 0% for placebo (p0.0001). Safety results were also favorable, as no serious adverse ...